natgillin/translations-raw huggingface dataset:
Tresiba comes in a pre-filled pen (FlexTouch) designed to be used with NovoFine or NovoTwist injection needles.
Tresiba dolazi u obliku napunjene brizgalice (FlexTouch) namijenjene uporabi s iglama za injekciju NovoFine ili NovoTwist.
Tresiba contains less than 1 mmol sodium (23 mg) per dose.
Tresiba sadrži manje od 1 mmol (23 mg) natrija po dozi.
Tresiba is a basal insulin for once-daily subcutaneous administration at any time of the day, preferably at the same time every day.
Tresiba je bazalni inzulin za supkutanu primjenu jednom dnevno, u bilo koje doba dana, po mogućnosti u isto vrijeme svakoga dana.
Tresiba is a basal insulin that forms soluble multi-hexamers upon subcutaneous injection, resulting in a depot from which insulin degludec is continuously and slowly absorbed into the circulation leading
Tresiba je bazalni inzulin koji tvori topive multiheksamere nakon supkutane injekcije, što rezultira stvaranjem depoa iz kojega se degludek inzulin neprestano i sporo apsorbira u cirkulaciju, što dovodi do ravnomjernog i stabilnog učinka lijeka Tresiba na snižavanje razine glukoze (vidjeti sliku 1).
Tresiba is a basal insulin that forms soluble multi-hexamers upon subcutaneous injection, resulting in a depot from which insulin degludec is continuously and slowly absorbed into the circulation leading to a flat and stable glucose-lowering-effect of Tresiba (see figure 1).
Tresiba je bazalni inzulin koji tvori topive multiheksamere nakon supkutane injekcije, što rezultira stvaranjem depoa iz kojega se degludek inzulin neprestano i sporo apsorbira u cirkulaciju, što dovodi do ravnomjernog i stabilnog učinka lijeka Tresiba na snižavanje razine glukoze (vidjeti sliku 1).
Tresiba is a replacement insulin that is very similar to the natural insulin with a difference that it is absorbed more slowly in the body and takes longer to reach its target.
Tresiba je zamjenski inzulin vrlo sličan prirodnom inzulinu.
Tresiba is available in two strengths.
Tresiba je dostupna u dvije jačine.
Tresiba is for subcutaneous use only.
Tresiba je namijenjena samo za supkutanu primjenu.
Tresiba is given as an injection under the skin (subcutaneous injection).
Tresiba se primjenjuje potkožnom (supkutanom) injekcijom.
Tresiba is presented as a clear and colourless solution for injection in a cartridge (300 units per 3 mL).
Tresiba dolazi u obliku bistre i bezbojne otopine za injekciju u ulošku (300 jedinica u 3 ml).
Tresiba is presented as a clear and colourless solution for injection in pre-filled pen (300 units per 3 mL).
Tresiba dolazi u obliku bistre i bezbojne otopine za injekciju u napunjenoj brizgalici (300 jedinica u 3 ml).
Tresiba is presented as a clear and colourless solution for injection in pre-filled pen (600 units per 3 mL).
Tresiba dolazi u obliku bistre i bezbojne otopine za injekciju u napunjenoj brizgalici (600 jedinica u 3 ml).
Tresiba is to be dosed in accordance with the individual patient’s needs.
Tresiba se treba dozirati sukladno individualnim potrebama bolesnika.
Tresiba is to be used once-daily with meal-time insulin and requires subsequent individual dosage adjustments.
Tresiba se primjenjuje jednom dnevno s inzulinom uz obrok i zahtijeva naknadne individualne prilagodbe doze.
Tresiba must not be administered intramuscularly as it may change the absorption.
Tresiba se ne smije primjenjivati intramuskularno jer to može promijeniti apsorpciju.
Tresiba must not be used in insulin infusion pumps.
Tresiba se ne smije koristiti u inzulinskim infuzijskim pumpama.
Tresiba pre-filled pen 100
Tresiba napunjena brizgalica 100
Tresiba pre-filled pen 200
Tresiba napunjena brizgalica 200
Tresiba2
Tresiba1
TREVICTA can help alleviate the symptoms of your disease and reduce the chance of your symptoms coming back.
TREVICTA može pomoći ublažiti simptome Vaše bolesti i spriječiti povratak simptoma.
TREVICTA can raise your levels of a hormone called "prolactin" found on a blood test (which may or may not cause symptoms).
alergijska reakcija lijek TREVICTA može podići razinu hormona koji se zove „prolaktin“ što se može vidjeti u testovima krvi (što može ili ne mora uzrokovati simptome).
TREVICTA doses for patients adequately treated with 1-monthly paliperidone palmitate injectable
Doze lijeka TREVICTA za bolesnike odgovarajuće liječene paliperidonpalmitatom u obliku 1- mjesečne injekcije
TREVICTA has not been systematically studied in patients with renal impairment (see section 5.2).
TREVICTA nije sustavno ispitivana u bolesnika s bubrežnim oštećenjem (vidjeti dio 5.2).
TREVICTA is a white to off-white prolonged release suspension for injection in a pre-filled syringe that your doctor or nurse will shake vigorously to resuspend the suspension before it is given as an injection.
TREVICTA je bijela do gotovo bijela suspenzija za injekciju s produljenim oslobađanjem u napunjenoj štrcaljki koju će Vaš liječnik ili medicinska sestra snažno protresti kako bi ju resuspendirali prije primjene u obliku injekcije.
TREVICTA is intended for intramuscular use only.
Lijek TREVICTA je namijenjen isključivo za intramuskularnu primjenu.
TREVICTA is not recommended in patients with moderate or severe renal impairment (creatinine clearance < 50 ml/min).
TREVICTA se ne preporučuje u bolesnika s umjerenim ili teškim bubrežnim oštećenjem (klirens kreatinina < 50 ml/min).
TREVICTA is not recommended in patients with moderate or severe renal impairment (creatinine clearance < 50 ml/min). (See sections 4.2 and 5.2).
TREVICTA se ne preporučuje u bolesnika s umjerenim ili teškim oštećenjem bubrega (klirens kreatinina < 50 ml/min). (Vidjeti dijelove 4.2 i 5.2).
TREVICTA is to be used only after the patient has been adequately treated with 1-monthly paliperidone palmitate injectable preferably for four months or more.
TREVICTA se primjenjuje samo ako je bolesnik primjereno liječen paliperidonpalmitatom u obliku 1- mjesečne injekcije, poželjno kroz četiri ili više mjeseci.
TREVICTA should be administered once every 3 months.
Lijek TREVICTA treba primijeniti jednom u svaka 3 mjeseca.
TREVICTA with alcohol
TREVICTA i alkohol
Trevicta1 paliperidone
Trevicta1 paliperidon
Tri or tetracyclic antidepressants (e.g. imipramine, clomipramine, mirtazapine) may impair the efficacy of pitolisant because they display histamine H1-receptor antagonist activity and possibly cancel the effect of endogenous histamine released in brain by the treatment.
Triciklični ili tetraciklični antidepresivi (npr. imipramin, klomipramin, mirtazapin) mogu smanjiti djelotvornost pitolizanta, jer pokazuju aktivnost antagonista H1-receptora histamina te mogu poništiti učinak endogenog histamina koji se liječenjem otpušta u mozak.
Tri>: 80000 673 (+357 22866700) cyprus_info@merck.com
Τηλ: 80000 673 (+357 22866700) cyprus_info@merck.com
triad of symptoms (meningism): neck stiffness, intolerance of bright light and headache, flu-like discomfort
trijas simptoma (meningizam): ukočenost vrata, nepodnošenje jakog svjetla i glavobolja, nelagoda nalik onoj kod gripe
Trial 1 enrolled 246 patients with narcolepsy and incorporated a 1 week up-titration period.
U Ispitivanje 1 bilo je uključeno 246 bolesnika s narkolepsijom uz titracijski period u trajanju od 1 tjedna.
Trial 3 is a Phase 3, parallel-group, multicentre, rollover study in patients with CF that includes patients from Trial 1 and Trial 2.
Ispitivanje 3 je multicentrično ispitivanje faze III koje se provodi na usporednim skupinama bolesnika s cističnom fibrozom s prijelazom ispitanika (engl. rollover) iz ispitivanja 1 i ispitivanja 2.
Trial characteristics
Plan kliničkog ispitivanja
Trial on different vaccination schedules:
Ispitivanje različitih rasporeda cijepljenja:
Trial outcome index results were supportive of FACT-L and LCS results a Values presented are for IRESSA versus carboplatin/paclitaxel.
Indeksirani rezultati ispitivanja podržali su FACT-L i LCS rezultate a Prikazane su vrijednosti za lijek IRESSA u usporedbi s karboplatinom/paklitakselom.
trial:
ARTEMIS:
Trials have indicated a t½ of about 2-5 hours.
Ispitivanja su pokazala da t½ iznosi približno 2–5 sati.
Trials have indicated a t½ of about 5–10 hours.
Ispitivanja su pokazala da t½ iznosi približno 5–10 sati.
Triangular tablet with mottled brown appearance embossed with the tablet strength on one side and the word “Pfizer” on the other.
Trokutasta, prošarana, smeđa tableta na kojoj je s jedne strane reljefno otisnuta jačina, a s druge strane riječ “Pfizer”.
Triazolam (oral)
koncentracija triazolama.
Triazolam 0.125, single dose 200, 4 doses ↑ > 20 fold ↑ 87% Ritonavir co-administration is likely to result in increased plasma concentrations of triazolam and is therefore contraindicated (see section 4.3).
Triazolam 0,125, jednokratna doza 200, 4 doze ↑ > 20 puta ↑ 87% Istodobno primijenjeni ritonavir vjerojatno povećava koncentracije triazolama u plazmi te je stoga kontraindiciran (vidjeti dio 4.3).
triazolam and midazolam (taken by mouth) - to help you sleep or for anxiety
triazolam i midazolam (primijenjeni kroz usta) – koriste se kao pomoć kod tegoba sa spavanjem ili za ublažavanje tjeskobe
Triazolam and oral (taken by mouth) midazolam
triazolam i oralni (uzima se kroz usta) midazolam
triazolam and oral (taken by mouth) midazolam (used to help you sleep and/or to relieve anxiety) simvastatin and lovastatin (used to lower blood cholesterol).
triazolam i peroralni (uzima se kroz usta) midazolam (primjenjuje se za liječenje poremećaja spavanja i/ili ublažavanje tjeskobe) simvastatin i lovastatin (primjenjuju se za snižavanje kolesterola u krvi)
triazolam and oral (taken by mouth) midazolam (used to help you sleep and/or to relieve anxiety).
triazolam i peroralni (uzima se kroz usta) midazolam (primjenjuje se za liječenje poremećaja spavanja i/ili ublažavanje tjeskobe)
triazolam with telaprevir is contraindicated.
triazolama s telaprevirom je kontraindicirana.
triazolam with Victrelis is
triazolama s lijekom Victrelis
triazolam, midazolam administered orally (sedatives/hypnotics) (for caution on parenterally administered midazolam, see section 4.5) sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil (PDE-5 inhibitors) simvastatin and lovastatin (HMG-CoA reductase inhibitors) (see section 4.5) ticagrelor (antiplatelets) (see section 4.5).
triazolam, peroralno primijenjen midazolam (sedativi/hipnotici) (mjere opreza za parenteralnu primjenu midazolama vidjeti dio 4.5) sildenafil - kada se primjenjuje za liječenje plućne arterijske hipertenzije, avanafil (PDE-5 inhibitori) simvastatin i lovastatin (inhibitori HMG-CoA reduktaze) (vidjeti dio 4.5) tikagrelor (antitrombotici) (vidjeti dio 4.5).
triazolam, oral midazolam and alprazolam due to potential for prolonged or increased sedation and respiratory depression
triazolam, peroralno primijenjen midazolam i alprazolam zbog moguće produljene ili pojačane sedacije i respiratorne depresije
triazole antifungal agents
lijekove za liječenje gljivičnih infekcija koji sadrže triazol
Trichuris suis (adult stages).
Trichuris suis (odrasli stadiji).
Trichuris vulpis (mature adult)
Trichuris vulpis (zreli odrasli)
tricitabine
emtricitabin
trict compliance with this
bolesnica podsjeti na važnost
trict compliance with this
bolesnici istakne važnost
Tricyclic antidepressant medicines such as amitryptiline, imipramine, or monoamine oxidase inhibitors, such as phenelzine, isocarboxazide, tranylcypromine or moclobemide.
triciklički antidepresivi poput amitriptilina, imipramina ili inhibitora monoaminooksidaze, poput fenelzina, izokarboksazida, tranilcipromina ili moklobemida.
TRICYCLIC ANTIDEPRESSANTS
TRICIKLIČKI ANTIDEPRESIVI
Tricyclic antidepressants (such as amitriptyline) and the antidepressant nefazodone.
triciklične antidepresive (poput amitriptilina) i antidepresiv nefazodon.
Tricyclic antidepressants (TCAs)
Triciklički antidepresivi (TCA)
Tricyclic antidepressants (TCAs; used to treat depression)
tricikličke antidepresive (za liječenje depresije)
Tricyclic antidepressants (used to treat depression).
triciklički antidepresivi (primjenjuju se u liječenju depresije)
Tricyclic antidepressants and noradrenaline re-uptake inhibitors
Triciklički antidepresivi i inhibitori ponovne pohrane noradrenalina
Trifexis 1040 mg/17.4 mg tablets: 4349 and 4 dimples
Trifexis 1040 mg/17,4 mg tablete: 4349 i 4 rupice
Trifexis 1040 mg/17.4 mg tablets: 4349 and 4 dimples
Trifexis 665 mg/11,1 mg tablete: 4347 i bez rupica Trifexis 1040 mg/17,4 mg tablete: 4349 i 4 rupice
Trifexis 1620 mg/27 mg tablets: 4336 and 5 dimples
Trifexis 1620 mg/27 mg tablete: 4336 i 5 rupica
Trifexis 270 mg/4.5 mg chewable tablets for dogs (3.9 – 6.0 kg) Trifexis 425 mg/7.1 mg chewable tablets for dogs (6.1 – 9.4 kg) Trifexis 665 mg/11.1 mg chewable tablets for dogs (9.5 – 14.7 kg) Trifexis 1040 mg/17.4 mg chewable tablets for dogs (14.8 – 23.1 kg) Trifexis 1620 mg/27 mg chewable tablets for dogs (23.2 – 36.0 kg)
Trifexis 270 mg/4,5 mg tablete za žvakanje za pse (3,9 – 6,0 kg) Trifexis 425 mg/7,1 mg tablete za žvakanje za pse (6,1 – 9,4 kg) Trifexis 665 mg/11,1 mg tablete za žvakanje za pse (9,5 – 14,7 kg) Trifexis 1040 mg/17,4 mg tablete za žvakanje za pse (14,8 – 23,1 kg) Trifexis 1620 mg/27 mg tablete za žvakanje za pse (23,2 – 36,0 kg)
Trifexis 270 mg/4.5 mg chewable tablets for dogs Trifexis 425 mg/7.1 mg chewable tablets for dogs Trifexis 665 mg/11.1 mg chewable tablets for dogs Trifexis 1040 mg/17.4 mg chewable tablets for dogs Trifexis 1620 mg/27 mg chewable tablets for dogs
Trifexis 270 mg/4,5 mg tablete za žvakanje za pse Trifexis 425 mg/7,1 mg tablete za žvakanje za pse Trifexis 665 mg/11,1 mg tablete za žvakanje za pse Trifexis 1040 mg/17,4 mg tablete za žvakanje za pse Trifexis 1620 mg/27 mg tablete za žvakanje za pse
Trifexis 270 mg/4.5 mg for dogs (3.9 – 6.0 kg) Trifexis 425 mg/7.1 mg for dogs (6.1 – 9.4 kg) Trifexis 665 mg/11.1 mg for dogs (9.5 – 14.7 kg) Trifexis 1040 mg/17.4 mg for dogs (14.8 – 23.1 kg) Trifexis 1620 mg/27 mg for dogs (23.2 – 36.0 kg)
Trifexis 270 mg/4,5 mg za pse (3,9 – 6,0 kg) Trifexis 425 mg/7,1 mg za pse (6,1 – 9,4 kg) Trifexis 665 mg/11,1 mg za pse (9,5 – 14,7 kg) Trifexis 1040 mg/17,4 mg za pse (14,8 – 23,1 kg) Trifexis 1620 mg/27 mg za pse (23,2 – 36,0 kg)
Trifexis 270 mg/4.5 mg tablets: 4333 and 2 dimples
Trifexis 270 mg/4,5 mg tablete: 4333 i 2 rupice
Trifexis 425 mg/7.1 mg spinosad 425 mg/milbemycin oxime 7.1 mg Trifexis 665 mg/11.1 mg spinosad 665 mg/milbemycin oxime 11.1 mg Trifexis 1040 mg/17.4 mg spinosad 1040 mg/milbemycin oxime 17.4 mg Trifexis 1620 mg/27 mg spinosad 1620 mg/milbemycin oxime 27.0 mg
Trifexis 425 mg/7,1 mg spinosad 425 mg/milbemicin oksim 7,1 mg Trifexis 665 mg/11,1 mg spinosad 665 mg/milbemicin oksim 11,1 mg Trifexis 1040 mg/17,4 mg spinosad 1040 mg/milbemicin oksim 17,4 mg Trifexis 1620 mg/27 mg spinosad 1620 mg/milbemicin oksim 27,0 mg
Trifexis 425 mg/7.1 mg tablets: 4346 and 3 dimples
Trifexis 425 mg/7,1 mg tablete: 4346 i 3 rupice
Trifexis 425 mg/7.1 mg tablets: 4346 and 3 dimples Trifexis 665 mg/11.1 mg tablets: 4347 and no dimples
Trifexis 425 mg/7,1 mg tablete: 4346 i 3 rupice
Trifexis 665 mg/11.1 mg tablets: 4347 and no dimples
Trifexis 665 mg/11,1 mg tablete: 4347 i bez rupica
Trifexis can prevent fleas for up to four weeks after a single administration because it kills adult fleas and reduces egg production.
Trifexis može spriječiti pojavu buha do četiri tjedna nakon jednog davanja VMP-a jer ubija odrasle buhe i smanjuje proizvodnju jajašca.
Trifexis chewable tablets are available in five different strengths (270 mg/4.5 mg, 425 mg/7.1 mg, 665 mg/11.1 mg, 1040 mg/17.4 mg and 1620/27 mg) to cover a range of dog weights.
Tablete za žvakanje Trifexis dostupne su u pet različitih jačina (270 mg/4,5 mg, 425 mg/7,1 mg, 665 mg/11,1 mg, 1040 mg/17,4 mg i 1620/27 mg) kako bi se pokrio cijeli raspon tjelesnih težina pasa.
Trifexis is a veterinary medicine that contains two active substances, spinosad and milbemycin oxime.
Trifexis je veterinarsko-medicinski proizvod koji sadrži dvije djelatne tvari, spinosad i milbemicin oksim.
Trifexis is used to treat and prevent flea infestations in dogs when there is also a need to prevent heartworm disease (roundworms that infect the heart and blood vessels and are transmitted by mosquitoes) and/or to treat gut infections by other types of worms (the nematodes hookworm, roundworm and whipworm).
Trifexis se koristi za liječenje i prevenciju infestacija buhama u pasa kada je indicirana istovremena prevencija bolesti srčanog crva (oblići koji infestiraju srce i krvne žile, a prenose se komarcima) i/ili za liječenje infestacija drugim tipovima crva (nematodni kukasti crv, oblić i bičasti crv).
Trifexis may also be used as part of a treatment strategy for the control of flea allergy dermatitis (an allergic reaction to flea bites).
Trifexis se može također koristiti kao dio strategije liječenja za kontrolu alergijskog dermatitisa na ugriz buhe (alergijske reakcije na ugriza buha).
Trifexis must not be used in puppies less than 14 weeks of age.
Trifexis se ne smije koristiti u štenadi mlađoj od 14 tjedana.
Trifexis should be given with food or immediately after feeding at a dose of 45 – 70 mg spinosad and
Trifexis se mora davati uz hranu ili neposredno nakon hranjenja u dozi od 45 – 70 mg spinosada i 0,75
Trifexis should not be given for more than six consecutive months in any one year.
Trifexis se ne smije davati više od šest uzastopnih mjeseci u jednoj godini.
Trifexis tablets should be administered to the dog with its food, or immediately after feeding.
Tablete Trifexis moraju se primijeniti psu s hranom ili neposredno nakon hranjenja.
Trifexis tablets should only be used when the veterinarian has confirmed diagnosis of mixed infection (or risk of infection, where prevention applies) at the same time (see section 4).
Tablete Trifexis smiju se dati samo nakon što je veterinar potvrdio dijagnozu više infestacija u isto vrijeme (ili rizika od infestacija tamo gdje je prevencija potrebna) (vidi odjeljak 4).
Trifexis-treated dogs were compared to dogs treated with milbemycin oxime alone.
Psi liječeni VMP-om Trifexis uspoređeni su sa psima liječenima samo milbemicin oksimom.
Trifluridine stops the growth of cancer cells.
Trifluridin zaustavlja rast stanica raka.
triglyceride levels2,5 Glucosuria
Glukozurija
Triglycerides (mg/dL)
Trigliceridi (mg/dl)
Triglycerides (TG) (mg/dL)a
Trigliceridi (TG) (mg/dl)a
Triglycerides,
Trigliceridi,
Triglycerides, mean % change from baseline
Trigliceridi, srednja vrijednost promjene od početne vrijednosti u
Trilayer capsule-shaped beige tablets of 11 mm in length and 5 mm in diameter printed with “PAL 6”
Troslojne tablete bež boje oblika kapsule dužine 11 mm i promjera 5 mm s otisnutom oznakom “PAL 6”
Trilayer capsule-shaped orange brown tablets of 11 mm in length and 5 mm in diameter printed with “PAL 1.5”.
Troslojne narančasto smeđe tablete oblika kapsule dužine 11 mm i promjera 5 mm s otisnutom oznakom “PAL 1.5”.
Trilayer capsule-shaped pink tablets of 11 mm in length and 5 mm in diameter printed with “PAL 9”
Troslojne tablete roza boje oblika kapsule dužine 11 mm i promjera 5 mm s otisnutom oznakom “PAL 9”
Trilayer capsule-shaped white tablets of 11 mm in length and 5 mm in diameter printed with “PAL 3”
Troslojne bijele tablete oblika kapsule dužine 11 mm i promjera 5 mm s otisnutom oznakom “PAL 3”
Trilayer capsule-shaped yellow tablets of 11 mm in length and 5 mm in diameter printed with “PAL 12”
Troslojne tablete žute boje oblika kapsule dužine 11 mm i promjera 5 mm s otisnutom oznakom “PAL 12”
trimethoprim
1,15 (1,10-1,20)
Trimethoprim
ANTIBIOTICI
trimethoprim
Ctrough
Trimethoprim
sulfametoksazol/trimetoprim
trimethoprim /sulfamethoxazole
trimetoprim /sulfametoksazol
trimethoprim PK ↔ sulfamethoxazole PK ↔
trimetoprim PK ↔ sulfametoksazol PK ↔
trimethoprim – used to treat infections.
trimetoprim - koristi se za liječenje infekcija.
Trimethoprim/sulfamethoxazole
Trimetoprim/sulfametoksazol
Trimethoprim/sulfamethoxazole (Co-trimoxazole)/Lamivudine (160 mg/800 mg once daily for 5 days/300 mg single dose)
(160 mg/800 mg jedanput dnevno tijekom 5 dana/300 mg jednokratna doza)
Trimethoprim/sulfamethoxazole (Co-trimoxazole)/Lamivudine (160 mg/800 mg once daily for 5 days/300 mg single dose)
trimetoprim/sulfametoksazol (kotrimoksazol)/lamivudin (160 mg/800 mg jedanput dnevno tijekom 5 dana
Trimethoprim/sulfamethoxazole (Co-trimoxazole)/Lamivudine (160mg/800mg once daily for 5 days/300mg single dose)
(160 mg/800 mg jedanput dnevno tijekom 5 dana/300 mg jednokratna doza)
Trimethoprim/sulfamethoxazole (Co-trimoxazole)/Lamivudine (160mg/800mg once daily for 5 days/300mg single dose)
trimetoprim/sulfametoksazol (kotrimoksazol)/lamivudin (160 mg/800 mg jedanput na dan tijekom 5 dana/300 mg u jednokratnoj dozi)
trimethoprim/sulfamethoxazole, an antibiotic to treat bacterial infections
trimetoprim/sulfametoksazol, antibiotik za liječenje bakterijskih infekcija
Trimethoprim: AUC  Sulfamethoxazole: AUC 
trimetoprim: AUC  sulfametoksazol: AUC 
trimoxazole is warranted, patients should be monitored clinically.
bolesnik bi se trebao klinički nadzirati.
Trion Pharma GmbH Frankfurter Ring 193a DE-80807 Munich Germany
Trion Pharma GmbH Frankfurter Ring 193a DE-80807 München Njemačka
Triple endpoint*
Trostruki ishod
Triple IT therapy (age-adjusted): days 1 and 22 VP-16 (100 mg/m2/day, IV): days 22-26
Trostruka i.t. terapija (prilagođena dobi): dani 1 i 22 VP-16 (100 mg/m²/dan, i.v.): dani 22-26
Triple IT therapy (age-adjusted): days 1, 29 VCR (1.5 mg/m2, IV): days 1, 29
Trostruka i.t. terapija (prilagođena dobi): dani 1, 29 VCR (1,5 mg/m², i.v.): dani 1, 29
Triple pack 1
Trostruko pakiranje 1
Triple pack 2
Trostruko pakiranje 2
Triple pack 3
Trostruko pakiranje 3
Triple therapies containing Victoza (1.2 mg or 1.8 mg) and metformin and either a sulphonylurea or a thiazolidinedione led to a reduction of between 1.3 and 1.5 percentage points compared with a reduction equal or less than 0.5 points without Victoza.
Trojne terapije koje sadrže lijek Victozu (1,2 mg ili 1,8 mg) i metformin i bilo sulfonilureju ili tiazolidinedion rezultirale su smanjenjem od 1,3 do 1,5 % u usporedbi sa smanjenjem jednakim ili manjim od 0,5 % bez lijeka Victoza.
Triple therapy with metformin and sulphonylurea (26 weeks)
Trojna terapija s metforminom i sulfonilurejom (26 tjedana)
Tris Base Tris HCl
Tris baza Tris HCl
TRISENOX 1 mg/ml, concentrate for solution for infusion
TRISENOX 1 mg/ml, koncentrat za otopinu za infuziju
TRISENOX 1 mg/ml, concentrate for solution for infusion Arsenic trioxide
TRISENOX 1 mg/ml, koncentrat za otopinu za infuziju arsenov trioksid
Trisenox contains less than 1 mmol sodium (23 mg) per dose.
TRISENOX sadrži manje od 1 mmol natrija (23 mg) po dozi.
TRISENOX is a concentrate for solution for infusion.
TRISENOX je koncentrat za otopinu za infuziju.
TRISENOX is indicated for induction of remission and consolidation in adult patients with relapsed/refractory acute promyelocytic leukaemia (APL), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor- alpha (PML/RAR-alpha) gene.
TRISENOX je indiciran za indukciju remisije i konsolidaciju u odraslih bolesnika s akutnom promijelocitnom leukemijom (APL) koja je u fazi relapsa/refraktorna na liječenje i karakterizirana je prisutnošću translokacije t(15;17) i/ili prisutnošću gena za alfa receptor za promijelocitnu leukemiju/retinoičnu kiselinu (PML/RAR-alfa).
Trisenox is normally given by a doctor or a nurse.
TRISENOX obično daje liječnik ili medicinska sestra.
TRISENOX is not recommended in children below 18 years of age.
TRISENOX se ne preporučuje u djece mlađe od 18 godina.
TRISENOX is supplied in glass ampoules as a concentrated, sterile, clear, colourless, aqueous solution that is prepared and diluted at the hospital and given as an infusion into a blood vessel.
TRISENOX je dostupan u staklenim ampulama u obliku koncentrirane, sterilne,bistre, bezbojne, vodene otopine koja se priprema i razrjeđuje u bolnici te se daje u krvnu žilu kao infuzija.
TRISENOX is used in adult patients with acute promyelocytic leukaemia (APL) whose disease has not responded to other therapies.
TRISENOX se koristi u odraslih bolesnika s akutnom promijelocitnom leukemijom (APL) čija bolest ne reagira na druga liječenja.